Skip to main content

Novo Nordisk

Company Profile
Novo Nordisk USE
Enterprise Value: $227 bn
Region: Europe

Novo Nordisk is a global healthcare company focused on the discovery, development, manufacturing and marketing of pharmaceutical products for the treatment of diabetes, obesity and haemophilia. Within the company’s diabetes and obesity segment it concentrates on insulin, GLP-1 and other protein-related products as well as delivery systems and needles and oral anti-diabetic drugs. Within the biopharmaceuticals segment, it covers haemophilia care, growth hormone therapy and hormone replacement therapy.

Impact Score: 46%

Many of Novo Nordisk’s therapies are given to patients who would either die or experience a dramatically lower quality of life without the therapies. While the drugs are providing benefits to a vulnerable population, it also tends to be one that is well-served.

Fundamental Quality: 76%

Novo is an impressive company driven by R&D and purpose, with a strong track record of innovation. ESG considerations are integrated within the company’s pursuit of doing business the “Novo Nordisk Way”, which is the basis for its guiding principles used in decision making.

Link to UN SDGs SDG 3
Novo Nordisk’s products are critical to the survival or quality of life of those with debilitating diseases, thus supporting SDG3.
Learn more
Impact calculator metric
(per £1m invested)
View our impact calculator
Recent stewardship topics
  • Drug pricing
Big impact in big pharma
WHEB Headshots 23
Find out

Sign up to impact fund updates

Sign up below to receive email updates on our impact investment funds.
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
{{ errors[0] }}
Authorised and regulated by the Financial Conduct Authority Copyright 2024© WHEB. All rights reserved Made by Thursday
How to invest